Selle FrÉdÉric, Heudel Pierre-Etienne, Hardy-Bessard Anne-Claire, Pozet Astrid, Meunier Jerome, Gladieff Laurence, Lotz Jean-Pierre, Provansal Magali, Augereau Paule, Berton Dominique, Bonichon-Lamichhane Nathalie, Orfeuvre Hubert, Pautier Patricia, Kalbacher Elsa, Tazi Yousef, Spaeth Dominique
Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris, France
Centre Léon Bérard, Lyon, France.
Anticancer Res. 2020 Jul;40(7):3939-3945. doi: 10.21873/anticanres.14385.
Trabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional PROSPECTYON study evaluated trabectedin/PLD in French clinical practice.
Patients with ROC after at least one platinum-based regimen received 1.1 mg/m trabectedin plus 30 mg/m PLD every 3 weeks. Efficacy and safety were evaluated in subgroups according to platinum-free interval [6-12 versus ≥12 months (partially or fully platinum sensitive, respectively)].
Recurrent disease was partially platinum-sensitive in 58 patients and fully sensitive in 33 patients treated between July 2014 and June 2016. Patients in both subgroups received a median of six cycles of trabectedin and PLD. The most common grade 3 or more toxicities were haematological. Median progression-free survival was 6 months for both subgroups.
Trabectedin/PLD is a valuable treatment option for partially or fully platinum-sensitive ROC.
曲贝替定与聚乙二醇化脂质体阿霉素（PLD）联合使用是铂敏感复发性卵巢癌（ROC）的一种有效联合治疗方案，尤其是对于在铂类治疗6 - 12个月内复发的疾病。非干预性的PROSPECTYON研究在法国临床实践中评估了曲贝替定/PLD。
至少接受过一种铂类方案治疗的ROC患者每3周接受1.1 mg/m²曲贝替定加30 mg/m² PLD治疗。根据无铂间期[6 - 12个月与≥12个月（分别为部分或完全铂敏感）]在亚组中评估疗效和安全性。
在2014年7月至2016年6月期间接受治疗的58例患者中复发疾病为部分铂敏感，33例患者为完全铂敏感。两个亚组的患者接受曲贝替定和PLD治疗的中位周期数均为6个周期。最常见的3级或更高级别的毒性为血液学毒性。两个亚组的中位无进展生存期均为6个月。
曲贝替定/PLD是部分或完全铂敏感ROC的一种有价值的治疗选择。
